The RNA therapeutics market was valued at USD 14.47 Billion in 2024, driven by the increasing FDA approvals for RNAi-based therapies across the globe. The market is anticipated to grow at a CAGR of 5.60% during the forecast period of 2025-2034, with the values likely to reach USD 24.95 Billion by 2034.
Base Year
Historical Year
Forecast Year
The market is poised for rapid growth driven by advancements in mRNA technology, particularly for vaccine development and gene silencing therapies, addressing a broad range of diseases with high precision and effectiveness.
Increasing investments in RNA-based drug research, coupled with growing FDA approvals for innovative therapies, are expanding the market's scope, offering novel treatment options for rare genetic disorders and complex diseases like cancer and cardiovascular conditions.
The rise of personalised medicine and RNA's ability to target specific genetic pathways are fostering demand, positioning RNA therapeutics as a transformative solution in healthcare, significantly boosting market expansion during the forecast period.
RNA therapeutics involve using RNA molecules to treat diseases by targeting gene expression at the RNA level. Key approaches include mRNA therapies, which instruct cells to produce therapeutic proteins, RNA interference (RNAi) to silence harmful genes, and antisense oligonucleotides (ASOs) to modify RNA splicing or stability. These therapies have significant potential for treating genetic disorders, cancers, and viral infections. By directly targeting the root causes of diseases at a molecular level, RNA therapeutics offer a promising and innovative approach to medicine.
Surge in FDA Approvals to Boost Market Value
The increasing prevalence of cancer and advancements in RNA-targeting technologies are significant drivers of market growth. In July 2024, Rgenta Therapeutics received FDA clearance for its Investigational New Drug (IND) application for RGT-61159, an innovative oral small molecule targeting RNA regulation. The drug is designed for the treatment of adenoid cystic carcinoma, colorectal cancer, solid tumors, and acute myeloid leukemia. This milestone highlights the shift toward RNA-based therapies in oncology. The approval is poised to accelerate investments in RNA-targeting drugs and expand the pipeline of RNA-based oncology treatments, boosting market value in the forecast period.
Rising Preference for Precision Medicine to Boost RNA Therapeutics Market Demand
Rising demand for precision medicine and breakthroughs in RNA-editing technologies drive market expansion. In November 2024, HuidaGene Therapeutics achieved FDA clearance for HG202, the first-ever CRISPR/Cas13 RNA-editing therapy designed for clinical use. This innovative treatment targets neovascular age-related macular degeneration, a leading cause of blindness. The development of HG202 underscores the growing potential of RNA-editing platforms. This approval is expected to foster competition, encourage global collaborations, and solidify RNA-editing’s role in addressing unmet medical needs, further enhancing the market’s growth trajectory during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Type
Market Breakup by Indication
Market Breakup by End User
Market Breakup by Region
Market Segmentation by Type to Witness Growth
The market share by type constitutes mRNA therapeutics, RNA interference (RNAi) therapeutics, antisense oligonucleotide (ASO) therapeutics and others. The mRNA therapeutics segment dominates the RNA therapeutics market by type, driven by the success of mRNA-based vaccines like those for COVID-19. Its rapid adaptability to emerging diseases and scalability in production gives it an edge.
North America leads the market share due to its advanced healthcare infrastructure, strong presence of biotechnology companies, and significant investments in R&D. The region benefits from a high prevalence of target diseases, robust regulatory frameworks, and government funding supporting RNA-based drug development. Additionally, North America hosts leading players pioneering RNA technology, including mRNA vaccines and gene silencing therapies, driving rapid market growth. The early adoption of innovative therapies and strategic partnerships between academia and industry further strengthen its dominance. This competitive edge positions North America as the key driver of the market globally.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Cambridge, Massachusetts, USA, Moderna was founded in 2010. The company is a pioneer in messenger RNA (mRNA) technology, having gained global recognition for its COVID-19 vaccine, Spikevax. Moderna is also advancing mRNA-based therapeutics across multiple disease areas, including oncology, rare genetic disorders, and infectious diseases. Its expanding portfolio focuses on developing mRNA medicines that deliver genetic instructions to cells, offering potential treatments for previously hard-to-address conditions.
BioNTech, based in Mainz, Germany, was established in 2008. The company is a leader in the development of mRNA-based therapeutics, most notably for its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer. BioNTech is expanding its portfolio into immuno-oncology, infectious diseases, and rare genetic disorders. Its innovative pipeline includes cancer immunotherapies using mRNA and other biologic approaches, alongside potential vaccines for various viral diseases, positioning it as a frontrunner in RNA therapeutics.
Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics. The company focuses on harnessing RNAi to silence specific genes involved in disease, offering treatments for genetic disorders, liver diseases, and rare conditions. Its portfolio includes Onpattro, the first RNAi-based drug approved for polyneuropathy in hereditary transthyretin amyloidosis, and several pipeline candidates targeting other genetic and metabolic diseases.
Ionis Pharmaceuticals, established in 1989 and headquartered in Carlsbad, California, specialises in antisense oligonucleotide (ASO) therapeutics. The company’s RNA-targeted therapies are designed to modify gene expression at the RNA level, addressing genetic disorders, neurodegenerative diseases, and cardiovascular conditions. Ionis' portfolio includes multiple FDA-approved drugs, such as Spinraza for spinal muscular atrophy, and several promising candidates for rare diseases, cancer, and amyloidosis, positioning it as a leader in RNA therapeutics.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Arcturus Therapeutics Holdings Inc., CureVac N.V., Sarepta Therapeutics, Inc., Wave Life Sciences Ltd., Sanofi S.A., and Novo Nordisk A/S.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share